Physician
Strategic Concepts Lab LLC
Strategic Concepts Lab LLC was paid $531K by Medicaid between Aug 2022 and Nov 2024, across 10 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 30% of everything it billed.
33Billing provider infoSTRATEGIC CONCEPTS LAB LLC
PLEASANTON, CA 94566
PLEASANTON, CA 94566
33aNPI1063140598assigned 08/11/2022
33bProvider typeClinical Pathology Physician
28Total paid$531K
24GClaims17,386
24DCodes billed10
24AFirst – last monthAug 2022 – Nov 2024
Compared with peers
Next to other Clinical Pathology Physician providers in California
Rank by total paid#2 of 5
Median peer was paid$13K
This provider vs. median40×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 2,150 | $49K | |
| 2023 | 7,007 | $190K | |
| 2024incomplete | 8,229 | $291K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 30% | 1,500 | 540 | $159K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 27% | 3,103 | 813 | $145K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 20% | 5,408 | 1,576 | $104K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 13% | 1,762 | 627 | $70K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 4.0% | 2,198 | 529 | $21K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.2% | 947 | 354 | $17K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.6% | 1,257 | 434 | $8K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 1.1% | 1,131 | 359 | $6K |
| 87634 | <1% | 27 | 27 | $62.39 | |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 0% | 53 | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAHMAD, HASHMAT (CEO)